Corvus Pharmaceuticals, Inc. — Director's Dealing 2018

Dec 14, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2018-12-12

Reporting Person: Verner Erik J. (V.P., Chemistry Research)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-12-12	Stock Option (Right to Buy)	$5.94	A	50000	Disposed	2028-12-12	Common Stock (50000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, $0.0001 par value	63773	Direct

Footnotes

F1: A portion of these shares is subject to a right of repurchase held by the Issuer.

F2: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 12, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.